Since the early 194Os, hormonal therapy has been the standard of treatment for metastatic prostate cancer. Yet, little is known about objective treatment response and its relation to prognosis. In the Veterans Administration Cooperative Urologic Research Group (VACURG), Bayard and associates' reported that 10 percent of patients treated with endocrine therapy alone lived lon 9 er than ten years. It appears that the natura history of prostate cancer is variable and probably includes a subset of patients whose response to hormonal treatment is unusually favorable. In an attempt to identify this patient group, we report our experience with hormonally treated patients with Stage D2 prostate cancer over a ten-year period.
Material and Methods
We reviewed the charts of 198 patients with Stage D2 prostate cancer (extrapelvic metastasis) treated with hormonal therapy at the University of Michigan Hospital from January 1981 to January 199;l. Patient ages ranged from thirty-three to eighty-five years, with a median of 64.5 years. All patients had biopsy-proved prostate adenocarcinoma and evidence of Stage D2 disease on bone scan, computerized tomography (CT) scan, or chest x-ray film. The majority of patients (136) presented initially with distant spread, while the remainder (62) progressed to advanced disease after unsuccessful treatment for localized cancer. Each received hormonal treatment when distant metastasis was apparent.
Hormonal therapy included single agent or combination treatment with estrogens, LHRH agonists, flutamide, or bilateral orchiectomy. Follow-up radiographic studies were analyzed after initiation of treatment.
Patients were evaluated for response using the criteria of the National Prostatic Cancer Project (NPCP).2 Criteria for a complete response (CR) included all of the following: (1) tumor masses which completely disappear, (2) normalization of acid phosphatase, (3) disappearance of osteolytic or osteoblastic lesions, (4) normalization of liver size or liver function tests, and (5) absence of new symptoms. Criteria for a partial response (PR) included any of the following: (1) recalcification of osteolytic lesions, (2) a 50 percent reduction in bone scan uptake or cross-sectional area of measurable lesions, (3) a 30 percent reduction in liver size or liver function tests, along with (4) normalization of acid phosphatase, and (5) absence of new symptoms or new sites of disease. In addition, all responders (complete and partial) had normalization of prostate-specific antigen (PSA) when measured.
Results
Of the 198 patients, 13 (6.6%) exhibited an objective treatment response documented by regression of a positive bone scan, CT scan, or chest x-ray film (Figs. 1 and 2). Four patients had a complete response and 9 had a partial response as judged by criteria of the National Prostatic Cancer Project (Table I) . Treatment response did not appear to be related to the method of hormonal ablation. Characteristics of the 13 responders included a mean age of 63.1 years and a Gleason score ranging from 5 to 9 with a median of 7. The nonresponder group included 185 patients with a mean age of 64.7 years. Pathology reports were available for 169 of these patients. The median Gleason score for the nonresponder group was also 7.
Of the responders, 5 patients initially presented with locoregional disease. Two of these patients presented initially as Stage B and were treated with radiation. One patient with Stage C disease underwent a radical prostatectomy.
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Stage Dl by pelvic lymph node dissection and received radiation. The remaining 8 patients in the responder group were diagnosed initially with Stage D2 disease. In all cases, patients received hormonal therapy when progression to Stage D2 was apparent. Sites of metastatic lesions in the responder group included bone in 10 patients, retroperitoneum or mediastinum in 3 patients, supraclavicular nodes in 2 patients, and lungs in 1 patient.
Kaplan-Meier survival estimates show a significant difference between the nonresponder curve and the responder curve ( Fig. 3) with p = 0.00006. M d e ian survival for the nonresponders is twenty-four months, which is similar to other reported data in Stage D2 disease.3 4 However, those patients with an objective treatment response have a median survival which has not yet been reached.
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Of the 13 hormonal treatment responders, 2
Metastatic prostate cancer has been tradipatients died at fifty months and one hundred tionally treated with androgen deprivation. eight months, respectively, for a mean survival Fifty years ago, Huggins and Hodges5 introof seventy-nine months. The 11 responders still duced castration and estrogen therapy as alalive have a median survival to date of thirtyternative forms of hormonal treatment. Alone months, For the hormonal treatment nonthough once widely prescribed, diethylstilbesresponders, median survival of the 107 expired trol is now used less frequently because of its patients was eighteen months. The remaining associated cardiovascular complications and the 78 living patients have been followed for a medevelopment of other medical agents not asdian of twelve months. sociated with cardiovascular morbidity, e.g., luteinizing hormone-releasing hormone (LHRH) agonists and antiandrogens.
Numerous studies have demonstrated the LHRH agonists to be equivalent to orchiectomy or DES as initial treatment of advanced prostate canceres7 Flutamide, a synthetic nonsteroidal antiandrogen, may be beneficial in combination with the LHRH agonists.s Median survival in Stage D2 prostate cancer patients treated with hormonal therapy is well documented and is generally reported at twenty-four to thirty months.3s4 Approximately 80 percent of patients will respond initially to hormonal ablation, suggesting that most prostate cancer cells are androgen sensitivea Because relapse following an initial response to hormonal manipulation is common, the hypothesis has been proposed that most prostatic carcinomas are heterogeneous and are composed of both androgen-dependent and androgen-independent cells. lo-l2 Androgen withdrawal presumably depletes the androgen-dependent cells. However, eventual replacement by androgen-independent cells frequently occurs, resulting in ultimate treatment failure.
As seen in the VACURG study, the time interval to failure is variable and includes a subset of patients who demonstrate a durable response to hormonal treatment. This translates into prolonged survival which we hypothesized would correlate with objective treatment response. We identified 13 of 198 patients (6.6%) who exhibited objective treatment response by NPCP criteria. When compared with hormonal treatment nonresponders over the same time period, a striking survival advantage was seen. Using Kaplan-Meier estimates, a statistically significant difference was apparent between the responder and nonresponder group (p = 0.00006). The median survival for the nonresponders is twenty-four months. In contrast, the median survival for the responders has not yet been reached but is greater than forty-four months. This observation identifies the small group of patients who will respond extraordinarily well to hormonal treatment of metastatic prostate cancer.
Why do some patients demonstrate an objective treatment response and not others? It is not clear but appears unrelated to site of metastasis, type of hormonal therapy, or previous treatment. Nevertheless, an objective treatment response is an important prognostic indicator that provides optimism in the usually dismal setting of Stage D2 prostate cancer. We are continuing to investigate other parameters that may provide early prediction of prolonged survival following hormonal therapy.
